SEER icon

Seer Inc

2.31 USD
-0.01
0.43%
At close Dec 20, 4:00 PM EST
1 day
-0.43%
5 days
-5.71%
1 month
0.87%
3 months
34.30%
6 months
40.00%
Year to date
19.07%
1 year
38.32%
5 years
-95.91%
10 years
-95.91%
 

About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Employees: 147

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

600% more call options, than puts

Call options by funds: $7K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

14% less capital invested

Capital invested by funds: $67.1M [Q2] → $57.7M (-$9.34M) [Q3]

14.38% less ownership

Funds ownership: 65.55% [Q2] → 51.17% (-14.38%) [Q3]

23% less funds holding

Funds holding: 91 [Q2] → 70 (-21) [Q3]

28% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 29

81% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 26

Research analyst outlook

We haven’t received any recent analyst ratings for SEER.

Financial journalist opinion

Neutral
GlobeNewsWire
4 weeks ago
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Neutral
GlobeNewsWire
1 month ago
Seer to Participate in Upcoming November Investor Conferences
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Seer to Participate in Upcoming November Investor Conferences
Neutral
Seeking Alpha
1 month ago
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Neutral
GlobeNewsWire
1 month ago
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
Neutral
GlobeNewsWire
2 months ago
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024
Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024
Neutral
GlobeNewsWire
3 months ago
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Seer Appoints Nicolas Roelofs to its Board of Directors
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors.
Seer Appoints Nicolas Roelofs to its Board of Directors
Neutral
GlobeNewsWire
4 months ago
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA.
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
Charts implemented using Lightweight Charts™